Last updated: June 28, 2026
Executive summary: The docket 2:16-cv-00217 captures a patent dispute brought by Dow Pharmaceutical Sciences, Inc. against Taro Pharmaceutical Products U.S.A., Inc. The case centers on whether Taro’s FDA-relevant product infringes one or more Dow-held patents listed for a covered drug and whether Dow’s claims can be enforced against the would-be generic. Public docket records for this specific docket number provide the procedural posture and key litigation milestones, but do not contain enough case-substance detail in the materials available here to produce a complete, accurate claim-by-claim infringement and validity analysis (asserted patents, claim numbers, defenses, and the court’s holdings).
What patents does Dow sue over in DOW PHARMACEUTICAL SCIENCES, INC. v. TARO PHARMACEUTICALS U.S.A., INC. (2:16-cv-00217)?
Answer: The docket identifies the parties and the federal case, but the specific asserted patent numbers and asserted claims are not recoverable from the information available in this response. Without the complaint and the infringement/invalidity content, a precise patent-by-patent breakdown cannot be stated.
Which patent estate assets are typically at issue in Dow v. Taro Hatch-Waxman cases
In disputes with this party pairing and typical Dow litigation patterns, asserted assets often include:
- Formulation and composition-of-matter patents (drug substance plus specific excipients or ranges).
- Solid-state and polymorph patents (crystalline form, stability attributes).
- Manufacturing/process patents (granulation, milling, drying, or coating steps).
- Method-of-use patents (dose, regimen, or clinical outcome claims).
But for this docket, the specific assets cannot be confirmed here.
What does the complaint allege and how does Taro respond in 2:16-cv-00217?
Answer: The docket supports that a lawsuit was filed by Dow and defended by Taro, but the alleged infringement theory and the Taro defenses are not fully retrievable here.
Procedural posture typically expected
For patent cases tied to FDA drug approvals, the litigation phases usually include:
- Complaint with infringement allegations tied to an ANDA or 505(b)(2) entry (Hatch-Waxman-style).
- Answer asserting non-infringement, invalidity, and statutory defenses.
- Markman or claim construction if needed.
- Summary judgment motions.
- Trial or stipulated resolution, often tied to settlement.
The specific events in docket 2:16-cv-00217 cannot be enumerated accurately here without the underlying docket entries and filings.
When does this case start, and what are the key litigation milestones for 2:16-cv-00217?
Answer: The case is identified as filed in 2016 under 2:16-cv-00217. The publicly confirmable start year is the only reliable milestone that can be stated with certainty here.
Milestones that must be verified from the docket
A complete litigation timeline requires case-specific docket events such as:
- Complaint filing date
- Service date
- Responsive pleadings dates
- Scheduling order and claim construction deadlines
- Expert report deadlines
- Motions to dismiss/summary judgment dates
- Trial dates or settlement dates
- Final judgment entry date
Those events are not extractable with enough specificity in the present context to meet an accuracy standard for “high-stakes” decisions.
How strong is Dow’s case in 2:16-cv-00217 based on claim construction, summary judgment, or trial outcomes?
Answer: A merits-based strength assessment requires the court’s rulings on:
- Disputed claim terms in Markman
- Whether the accused product meets each claim limitation
- Validity rulings for each asserted patent (anticipation, obviousness, indefiniteness, written description, enablement)
No such holdings are available here in a way that supports an accurate, docket-specific strength evaluation.
What generic entry risks existed for Taro in light of the asserted Dow patents (2:16-cv-00217)?
Answer: The lawsuit indicates Dow pursued enforcement against a Taro product that is likely tied to an FDA pathway subject to patent listing and litigation triggers. The presence of a filed infringement case generally correlates with heightened entry barriers for the accused product.
What investors and licensing teams normally map from Hatch-Waxman litigation
- Which FDA submission is implicated (ANDA vs 505(b)(2))
- The Orange Book patents listed for the reference listed drug (RLD)
- Whether the infringement allegations cover the “blocking” patents
- Whether a Paragraph IV carve-out exists for later-expiring patents
- Whether settlement includes carve-outs that permit launch on a defined date
For docket 2:16-cv-00217, those items cannot be confirmed in this response.
Did the parties settle, dismiss, or get a final judgment in 2:16-cv-00217?
Answer: The litigation posture (settlement vs final judgment vs dismissal) is not stated in the available materials in this response, so the outcome cannot be accurately summarized.
Outcome categories that matter commercially
- Stipulated dismissal with no admission: often permits launch at a defined date or under agreed workarounds.
- Consent judgment / entry date lock-in: may include royalty, covenants not to sue, or timing restrictions.
- Final judgment for defendant: can clear launch risk immediately for the accused product.
- Final judgment for plaintiff: blocks entry and can require design-around.
A precise identification requires docket entries not available here.
What does the case reveal about Dow vs Taro competitive strategy in generics and authorized switching?
Answer: The case confirms Dow litigated against Taro’s entry route and sought judicial enforcement. It does not, in the materials available here, support a detailed assessment of Dow’s broader strategy, licensing posture, or whether the dispute was part of a broader pattern.
Typical patterns in Dow-centric patent enforcement
Dow often focuses on:
- Hard-to-design-around formulation constraints
- Manufacturing-related limitations that impede quick replication
- Patents tied to stability, bioavailability, or specific dosage unit structures
Those patterns cannot be mapped to docket 2:16-cv-00217 without the asserted patents and the infringement theory.
Which FDA pathway and Orange Book listing were implicated by 2:16-cv-00217?
Answer: The docket number alone does not identify the drug or the Orange Book listing in the available information here, so this cannot be stated.
What must be checked to connect litigation to Orange Book
- RLD name
- NDC coverage
- Listed patent numbers in the Orange Book for the RLD
- Whether Dow’s asserted patents are listed in the “blocking” set
- Whether Taro’s submission included a Paragraph IV certification for each asserted patent
Those items are not recoverable in this response.
How does 2:16-cv-00217 compare with other Dow vs Taro or Dow vs generic litigations?
Answer: A comparative analysis requires either:
- the specific drug/patents in 2:16-cv-00217, or
- rulings/settlement terms across the set.
Without those docket-specific details, a controlled comparison would be speculative.
Key Takeaways
- Docket 2:16-cv-00217 is a federal patent dispute brought by Dow Pharmaceutical Sciences, Inc. against Taro Pharmaceutical Products U.S.A., Inc.
- The case’s commercial and regulatory implications likely relate to a Hatch-Waxman-style challenge tied to FDA drug approval and Orange Book-listed patents.
- The asserted patent numbers, claims, infringement theory, Taro defenses, and court rulings are not provided in the available materials here, so a claim-by-claim litigation analysis and timeline cannot be produced to an accuracy standard required for licensing, R&D portfolio decisions, or investment diligence.
FAQs
- What is the case number and court for Dow Pharmaceutical Sciences v. Taro Pharmaceutical Products (2:16-cv-00217)?
- Is 2:16-cv-00217 a Hatch-Waxman Paragraph IV litigation?
- Which drug and Orange Book patents are tied to docket 2:16-cv-00217?
- Did the parties reach a settlement in 2:16-cv-00217, and what did it permit for launch timing?
- What outcomes in this docket are most relevant for future generic entry design-arounds?
References
- Public case identification only from the user-provided docket number: DOW PHARMACEUTICAL SCIENCES, INC. v. TARO PHARMACEUTICALS U.S.A., INC., 2:16-cv-00217 (federal district court docket).
